14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
EQ vs CLYM: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Equillium, Inc. (EQ) is the stronger overall head-to-head candidate over Climb Bio, Inc. (CLYM) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow, Options & Positioning). EQ carries a Unified Composite Score of 48.6/100 (HOLD) at $1.06 (1.5x Forward P/E, 0.0% operating margin), whereas CLYM carries 43.7/100 (HOLD) at $9.19 (N/M Forward P/E, 0.0% operating margin).
Growth vs. Quality Trade-Off: EQ earns the overall head-to-head edge with a stronger Unified Composite Score (48.6/100 HOLD vs. CLYM 43.7/100 HOLD) and 1.54β · 89% Vol risk profile, whereas CLYM leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: EQ is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.7); meanwhile CLYM is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 40.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on EQ vs CLYM. Trailing 12-month operating profitability (EQ 0.0% vs CLYM 0.0%) and valuation multiples (EQ 1.5x vs CLYM N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $545.1M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ EQ vs CLYM Key Questions & Quantitative Answers
As of Nov 20, 2026, Equillium, Inc. (EQ) is the stronger overall head-to-head candidate over Climb Bio, Inc. (CLYM) in the Tradestie Institutional Equity Comparison Engine, winning 4–4 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow, Options & Positioning). EQ carries a Unified Composite Score of 48.6/100 (HOLD) at $1.06 (1.5x Forward P/E, 0.0% operating margin), whereas CLYM carries 43.7/100 (HOLD) at $9.19 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: EQ earns the overall head-to-head edge with a stronger Unified Composite Score (48.6/100 HOLD vs. CLYM 43.7/100 HOLD) and 1.54β · 89% Vol risk profile, whereas CLYM leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: EQ is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.7); meanwhile CLYM is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 40.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CLYM leads the Growth & Scale pillar: EQ posts -52.3% YoY revenue growth and +0.0% YoY earnings growth on $4.4M TTM revenue (100.0% gross margin, 0.0% operating margin), compared with CLYM at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, EQ generates $4.4M in USD-normalized revenue versus N/A for CLYM. In operating R&D and SG&A reinvestment, EQ deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CLYM.
EQ screens cheaper on headline valuation multiples. EQ trades at 1.5x Forward P/E, 1.5x Trailing P/E, N/M PEG, and 8.1x EV/Revenue (unreported FCF margin), whereas CLYM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EQ (-59.0% ROE) versus CLYM (-29.3% ROE) capital efficiency.
In options market volatility and institutional positioning, EQ carries 261.3% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.54β · 89% Vol realized risk). By comparison, CLYM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.42β · 106% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.